ClinicalTrials.gg
CompletedNCT03960580Updated Dec 21, 2023Results posted

Study Evaluating the Efficacy and Safety of Intranasal Administration of OPN-375 in Subjects With Chronic Rhinosinusitis Without the Presence of Nasal Polyps

A Phase 3 interventional study of OPN-375 in Chronic Rhinosinusitis, sponsored by Optinose US Inc.. Completed at 87 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-12-21.

Sponsored by Optinose US Inc. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
223
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 71 studies in Rhinosinusitis with a site in United States — 11 open to participants now, 18 under way, 7 of them phase 3. Rhinosinusitis · United States.

Enrollment
9th of 55
223 · median 59
Started
2019
with 1 other
Phase 3
12 of 71
2 open now
Registered
44th of 71
by date
Lead sponsor
3 of 71
Optinose US Inc.

Among the 71 studies in Rhinosinusitis with a site in United States, this one is the 9th largest by enrollment of the 55 interventional ones that give a count, is one of 2 that started in 2019, is one of 12 in phase 3, and was the 44th registered.

Rhinosinusitis

251 studies on the registry are indexed under Rhinosinusitis; 69 are open to participants now.

Browse Rhinosinusitis studies →

Open to participants now

11 of the 71 studies in Rhinosinusitis with a site in United States are open now. Recruiting first, the newest first:

6 more — sign in →

All 11 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 33 Rhinosinusitis studies recruiting now, 14 (42%) set no upper age limit and 13 (39%) stop at 75 or younger; 4 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 71 studies in Rhinosinusitis with a site in United States, or all of them as a file.
02

Study summary

This is a 24-week randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the efficacy and safety of intranasal administration of 186 and 372 μg twice daily (BID) of OPN-375 in subjects with chronic Rhinosinusitis (CRS) without nasal polyps

Read the detailed description

The primary objective of this study is to compare the efficacy of intranasal administration of twice-daily doses of 186 and 372 µg of OPN-375 (fluticasone propionate) with placebo in subjects with chronic rhinosinusitis using the following co-primary endpoints:

  1. A change from baseline in symptoms as measured by the average morning composite score of nasal congestion, facial pain or pressure sensation, and nasal discharge (anterior and/or posterior) at the end of Week 4.
  2. A change from baseline to Week 24/Early Termination (ET) in the average percent of the volume opacified in the ethmoid and maxillary sinuses.
03

Conditions studied

  • Chronic Rhinosinusitis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. men or women aged 18 years and older at baseline visit
  2. women of child bearing potential must be abstinent, or if sexually active,

    1. be practicing an effective method of (eg, prescription oral contraceptives, contraceptive injections, contraceptive patch, intrauterine device, double-barrier method [eg, condoms, diaphragm, or cervical cap with spermicidal foam, cream, or gel], or male partner sterilization) before entry and throughout the study, or
    2. be surgically sterile (have had a hysterectomy or bilateral oophorectomy, tubal ligation, or otherwise be incapable of pregnancy), or
    3. be (amenorrhea for at least 1 year)
  3. women of must have a negative urine pregnancy test at Visit 1 (Screening)
  4. must have a history of chronic sinusitis and be currently experiencing 2 or more of the following symptoms, 1 of which has to be either nasal congestion or nasal discharge (anterior and/or posterior nasal discharge) for equal to or greater than 12 weeks:

    • nasal congestion
    • nasal discharge (anterior and/or posterior nasal discharge)
    • facial pain or pressure
    • reduction or loss of smell
  5. endoscopic evidence of nasal mucosal disease, with edema or purulent discharge; or polyps/polypoid tissue \<Grade 1 in middle meatus, bilaterally
  6. must have confirmatory evidence via a computed tomography(CT) scan of bilateral sinus disease (have at least 1 sinus on each side of nose with a Lund-Mackay score of ≥1)
  7. baseline CT scan must show a combined ≥25% opacification of the ethmoid sinuses and ≥25% opacification of at least 1 maxillary sinus
  8. must have at least moderate symptoms (as defined in protocol) of nasal congestion as reported by the subject, on average, for the 7-day period preceding Visit 1 (Screening) run-in
  9. must have an average morning score of at least 1.5 for congestion on the Nasal Symptom Scale (as defined in protocol) recorded on the subject diary over a 7-day period during the first 14 days of the single-blind run-in period
  10. must demonstrate an ability to correctly complete the daily diary during the run-in period to be eligible for randomization
  11. Subjects with comorbid asthma or chronic obstructive pulmonary disorder () must be stable with no exacerbations (eg, no emergency room visits, hospitalizations, or oral or parenteral use) within the 3 months before Visit 1 (Screening). Inhaled corticosteroid use must be limited to stable doses of no more than 1,000 μg/day of beclomethasone (or equivalent) for at least 3 months before Visit 1 (Screening) with plans to continue use throughout the study.
  12. Subjects with aspirin-exacerbated respiratory disease, who have undergone aspirin desensitization and are receiving daily aspirin therapy, must be receiving therapy for at least 6 months prior to Visit 1.
  13. must be able to cease treatment with intranasal steroids, inhaled corticosteroids (except permitted doses listed above for asthma and COPD) at the screening visit.
  14. must be able to cease treatment with oral and nasal decongestants and antihistamines at Visit 1 (Screening)
  15. must be able to use the exhalation delivery system correctly; all subjects will be required to demonstrate correct use with the practice exhalation delivery system (EDS) at Visit 1 (Screening).
  16. must be capable, in the opinion of the investigator, of providing to participate in the study. Subjects must sign an informed consent document indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study.

Exclusion criteria

Exclusion Criteria:

  1. women who are pregnant or lactating
  2. inability to have each nasal cavity examined for any reason, including nasal septum deviation
  3. inability to achieve bilateral nasal airflow
  4. is currently taking XHANCE®
  5. have previously used XHANCE® for more than 1 month and did not achieve an adequate symptomatic response
  6. the nasal/sinus anatomy prevents the accurate assessment of sinus volume via CT scan
  7. history of sinus or nasal surgery within 6 months before Visit 1 or has not healed from a prior sinus or nasal surgery
  8. have current evidence of odontogenic sinusitis, sinus mucocele (the affected sinus is completely opacified and either the margins are expanded and/or thinned OR there are areas of complete bone resorption resulting in bony defect and extension of the "mass" into adjacent tissues), evidence of allergic fungal sinusitis, or evidence of complicated sinus disease (including, but not limited to, extension of inflammation outside of the sinuses and nasal cavity)
  9. have a paranasal sinus or nasal tumor
  10. have polyp grade ≥1 (polyp that is free on 5 sides and has a stalk) on either side of the nose as determined by the nasoendoscopy at screening
  11. have a nasal septum perforation
  12. have had more than 1 episode of epistaxis with frank bleeding in the month before Visit 1 (Screening)
  13. have evidence of significant mucosal injury, ulceration (eg, exposed cartilage) on Visit 1 (Screening) nasal examination/nasoendoscopy
  14. have current, ongoing rhinitis medicamentosa (rebound rhinitis)
  15. have significant oral structural abnormalities (eg, a cleft palate)
  16. have a diagnosis of cystic fibrosis
  17. history of Churg-Strauss syndrome or dyskinetic ciliary syndromes
  18. symptom resolution or last dose of antibiotics for purulent nasal infection, acute sinusitis, or upper respiratory tract infection has not occurred before Visit 1 or was less than 4 weeks before the CT scan. Potential subjects presenting with any of these infections may be rescreened 4 weeks after symptom resolution.
  19. planned sinonasal surgery during the period of the study
  20. allergy, , or to or steroids
  21. has used oral steroids in the past for treatment of chronic sinusitis and did not experience any relief of symptoms
  22. has a steroid eluting sinus stent still in place within 30 days of Visit 1
  23. allergy or hypersensitivity to any in study drug
  24. exposure to any glucocorticoid treatment with potential for systemic effects (eg, oral, parenteral, intraarticular, or epidural steroids, high dose topical steroids) within 1 month before Visit 1 (Screening); except as noted in inclusion criteria for subjects with comorbid asthma or
  25. have nasal candidiasis
  26. history or current diagnosis of any form of glaucoma or ocular hypertension
  27. history of intraocular pressure elevation on any form of steroid therapy
  28. history or current diagnosis of the presence (in either eye) of a subcapsular cataract
  29. history of immunodeficiency
  30. any serious or unstable concurrent disease, psychiatric disorder, or any significant condition that, in the opinion of the investigator could confound the results of the study or could interfere with the subject's participation or compliance in the study
  31. have a positive drug screen or a recent (within 1 year of Visit 1 [Screening]) history of drug or alcohol abuse, or dependence that, in the opinion of the investigator could interfere with the subject's participation or compliance in the study
  32. have participated in an drug clinical trial within 30 days of Visit 1 (Screening)
  33. have received mepolizumab (Nucala®), reslizumab (Cinquair®), dupilumab (Dupixent®), omalizumab (Xolair®), or benralizumab (Fasenra™) within 6 months of Visit 1 (Screening)
  34. is using strong cytochrome P450 3A4 () inhibitors (eg, ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, ketoconazole, telithromycin, conivaptan, lopinavir, voriconazole)
  35. is an employee of the investigator or study center, with direct involvement in the proposed study or other studies under the direction of that investigator or study center, or is a family member of the employee or the investigator.
  36. patients who report unexplained worsening of vision within the past 3 months (e.g. difficulty reading or seeing traffic signs from a distance). A diagnosis of presbyopia established by an eye care professional is not exclusionary.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
223 participants (actual)

Study arms

  • Active comparator
    OPN-375 186 μg BID

    OPN-375 186 μg BID x 24 Weeks

    Drug: OPN-375

  • Active comparator
    OPN-375 372 μg BID

    OPN-375 372 μg BID x 24 Weeks

    Drug: OPN-375

  • Placebo comparator
    Placebo

    Matching Placebo BID x 24 Weeks

    Drug: OPN-375

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Symptoms as Measured by a Composite Score for Each Symptom of Nasal Congestion, Facial Pain or Pressure Sensation, and Nasal Discharge (Anterior and/or Posterior) at the End of Week 4

    Change from baseline to the end of Week 4 in average total instantaneous AM scores (evaluation of symptom severity immediately preceding the time of scoring) for each symptom: nasal congestion, nasal discharge (anterior and/or posterior), facial pain/pressure sensation. Baseline scores are the averaged total instantaneous AM scores over the last 7 days of the single blind run in period, and the end of Week 4, scores are averaged over the 7 days from the subject diary. Range of scores for each nasal symptom is 0= none, 1 = mild, 2 = moderate, 3 = severe. Composite score is a sum of the 3 symptom scores and will range from 0 to 9.

    Time frame: 4 Weeks

  2. Change From Baseline to Week 24/Early Termination (ET) in the Average Percent of the Volume Opacified (APOV) in the Ethmoid and Maxillary Sinuses.

    Change from baseline to Week 24/ET in the average percent of ethmoid and maxillary sinus volume opacified as measured by CT. Percent volume opacified can range from 0% to 100%. Outcome measure is the percentage change from percent opacification at baseline to percent opacification at Week 24; therefore, change in opacification volume can range from -100% to 100%. For example, if Baseline opacification was 68.22% and Week 24 opacification was 66.11%, then the change would be reported as -2.11%.

    Time frame: Baseline, Week 24

Secondary outcomes

  1. Change From Baseline to Week 4 in Each of the 4 Individual Cardinal Chronic Rhinosinusitis (CRS) Symptoms (AM, Instantaneous).

    The 4 individual CRS symptoms are: congestion, facial pain or pressure sensation, nasal discharge (anterior and/or posterior), and sense of smell. Range of scores for each nasal symptom is 0= none, 1 = mild, 2 = moderate, 3 = severe. The scores at baseline and week 4 are calculated by averaging the score reported for the individual symptom over 7 days prior to the timepoint. The value provided in the results is calculated by subtracting the score at Week 4 from the score at Baseline; therefore, scores reported here can range from -3 to 3.

    Time frame: Baseline, Week 4

  2. Time to First Acute Exacerbation of Chronic Sinusitis

    Comparing the distribution of time to first acute exacerbation of chronic sinusitis across treatment groups. An exacerbation of chronic sinusitis is defined as a worsening of symptoms that requires escalation of treatment.

    Time frame: 24 Weeks

  3. Change From Baseline to Defined Timepoints - Subject Symptoms and Functioning as Measured by the Sinonasal Outcome Test - 22-item (SNOT-22) Total Score and Sub Domains

    The SNOT-22 is a subject-completed questionnaire that consists of 22 symptoms and social/emotional consequences of their nasal disorder across several domains including: rhinologic, extra-nasal rhinologic, ear/facial pain, psychological dysfunction, and sleep dysfunction. Total scores range from 0-110. The score range for each domain are as follows: Rhinologic: 0-30; Extra-nasal rhinologic: 0-15; Ear/facial: 0-25; Psychological dysfunction: 0-35; Sleep dysfunction: 0-25. Each item is rated as follows: 0=no problem, 1=very mild problem, 2=mild or slight problem, 3=moderate problem, 4=severe problem, 5=problem as bad as it can be, and total scores are calculated by adding scores together. The values reported here are calculated by subtracting the score reported at baseline from the score reported at Week 24 and, therefore, can range from the negative maximum score value to the positive maximum score value.

    Time frame: 24 Weeks

  4. Change From Baseline to Week 8 and 12 in Composite Symptom Score (Congestion, Facial Pain or Pressure Sensation, and Nasal Discharge) for the Total Population and Patients With and Without Previous Sinus Surgery.

    Change from baseline in average total instantaneous AM scores (evaluation of symptom severity immediately preceding the time of scoring) for each symptom: nasal congestion, nasal discharge (anterior and/or posterior), facial pain/pressure sensation. Range of scores for each symptom is 0=none, 1=mild, 2=moderate, 3=severe. The composite score is the sum of the 3 symptom scores and will range from 0-9. Scores reported at each timepoint are the averaged total instantaneous AM scores over the last 7 days before the given timepoint. The values presented here are calculated by subtracting the score at Baseline from Week 8 and Week 12, respectively.

    Time frame: 8 weeks, 12 weeks.

  5. Change From Baseline to Weeks 8 and 12 in Nasal Congestion Measured by Instantaneous Morning (AM) and Evening (PM) Diary Symptom Scores

    Subjects will report instantaneous (evaluation of symptom severity immediately preceding the time of scoring) symptoms. The Nasal Symptom Scale scores as 0=none, 1=mild-symptoms clearly present but minimal awareness, and easily tolerated, 2= moderate - definite awareness of symptoms that is bothersome but tolerable, 3 = severe - symptoms that are hard to tolerate, cause interference with activities or daily living.

    Time frame: 8 Weeks; 12 Weeks

  6. Change From Baseline to Weeks 8 and 12 in Nasal Discharge (Anterior and/or Posterior) Measured by Instantaneous AM and PM Diary Symptom Scores

    Subjects will report instantaneous (evaluation of symptom severity immediately preceding the time of scoring) scores. The Nasal Symptom Scale scores as 0=none, 1=mild-symptoms clearly present but minimal awareness, and easily tolerated, 2= moderate - definite awareness of symptoms that is bothersome but tolerable, 3 = severe - symptoms that are hard to tolerate, cause interference with activities or daily living

    Time frame: Baseline, Week 8, Week 12

  7. Change From Baseline to Weeks 8 and 12 in Facial Pain or Pressure Sensation Measured by Instantaneous AM and PM Diary Symptom Scores

    Subjects will report instantaneous (evaluation of symptom severity immediately preceding the time of scoring) symptoms. The Nasal Symptom Scale scores as 0=none, 1=mild-symptoms clearly present but minimal awareness, and easily tolerated, 2= moderate - definite awareness of symptoms that is bothersome but tolerable, 3 = severe - symptoms that are hard to tolerate, cause interference with activities or daily living.

    Time frame: Baseline, Week 8, Week 12

  8. Change From Baseline to Weeks 8 and 12 in Sense of Smell Scores Measured by Instantaneous AM and PM Diary Symptom Scores

    Subjects will report instantaneous (evaluation of symptom severity immediately preceding the time of scoring) symptoms. The sense of smell scored as 0= normal, 1=slightly impaired, 2=moderately impaired, 3=absent.

    Time frame: Baseline, Week 8, Week 12

  9. Change From Baseline to Week 24/ET in the Average Percent of the Volume Opacified in the Ethmoid and Maxillary Sinuses for Patients With and Without Previous Sinus Surgery

    Change from Baseline to Week 24/ET in the average percent of ethmoid and maxillary sinus volume opacified as measured by CT for subgroups in patients without and without previous sinus surgery. Percent volume opacified of the combined ethmoid and maxillary sinuses can range from 0% to 100%. Outcome measure is percentage change from percent opacification at baseline to percent opacification at Week 24; therefore, change in opacification volume can range from -100% to 100%. For example, if Baseline opacification was 68.22% and Week 24 opacification was 66.11%, then the change would be reported as -2.11%.

    Time frame: Baseline, Week 24

  10. Change From Baseline to Week 24/ET in the Lund-Mackay Staging System Total Score

    Lund-Mackay Staging System: Lund-Mackay (LM) system (Lund and Mackay, 1993) assigns to each of 10 sinus cavities (left and right maxillary, anterior ethmoid, posterior ethmoid, sphenoid, and frontal) a score of 0 (no opacification), 1 (partial opacification), or 2 (total opacification), plus a 0-2 score for each of the left and right ostiomeatal complex (OMC). The total LM score for a CT scan ranges from 0-24.

    Time frame: Baseline, Week 24

  11. Change From Baseline to Week24/ET in the Lund-Mackay Staging System Scores for Each Sinus Pair

    Lund-Mackay Staging System: Lund-Mackay (LM) system (Lund and Mackay, 1993) assigns to each of 10 sinus cavities (left and right maxillary, anterior ethmoid, posterior ethmoid, sphenoid, and frontal) a score of 0 (no opacification), 1 (partial opacification), or 2 (total opacification). Each sinus pair (left and right side) listed below can achieve a total score of 0-4 (sum of 0-2 for each side). The values reported below are calculated by subtracting the total score at baseline from the total score at Visit 6 (week 24).

    Time frame: Baseline, Week 24

  12. Change From Baseline to Week 24/ET in the Average Percent of Sinus Volume Occupied by Disease in the Worst Maxillary Sinus, as Measured by CT Scan Assessment.

    Percent volume opacified of the worst maxillary sinus can range from 0% to 100%. The outcome measure is the percentage change from percent opacification of the worst maxillary sinus at baseline to the percent opacification of the same maxillary sinus at Week 24; therefore, change in opacification volume can range from -100% to 100%.

    Time frame: Baseline, Week 24

  13. Change From Baseline to Week 24/ET in the Average Percent of Sinus Volume Occupied by Disease in the Worst Ethmoid Sinus, as Measured by CT Scan Assessment.

    Percent volume opacified of the worst ethmoid sinus can range from 0% to 100%. The outcome measure is the percentage change from percent opacification of the worst ethmoid sinus at baseline to the percent opacification of the same ethmoid sinus at Week 24; therefore, change in opacification volume can range from -100% to 100%.

    Time frame: 24 weeks

  14. Change From Baseline to Week 24/ET in the Average Percent of Sinus Volume Occupied by Disease in the Worst Sinus Between Maxillary and Ethmoid Sinuses, as Measured by CT Scan Assessment.

    Percent volume opacified of the worst sinus can range from 0% to 100%. The outcome measure is the percentage change from percent opacification of the worst sinus at baseline to the percent opacification of the same sinus at Week 24; therefore, change in opacification volume can range from -100% to 100%.

    Time frame: 24 weeks

  15. Change From Baseline to Week24/ET in the Lund-Mackay Staging System Scores for the Ethmoids and Maxillary Sinuses Combined

    Lund-Mackay Staging System: Lund-Mackay (LM) system (Lund and Mackay, 1993) assigns to each of 10 sinus cavities (left and right maxillary, anterior ethmoid, posterior ethmoid, sphenoid, and frontal) a score of 0 (no opacification), 1 (partial opacification), or 2 (total opacification), plus a 0-2 score for each of the left and right ostiomeatal complex (OMC). The values reported for this outcome are the change in total opacification of the left an dright maxillary and ethmoid sinuses (Visit 6 \[Wk 24\] score minus Baseline score). Each visit score can range from a total of 0-12 (sum of 0-2 score assigned for each of left and right maxillary, left and right anterior ethmoid, and left and right posterior ethmoid).

    Time frame: 24 Weeks

  16. Change From Baseline to Week 24/ET in the Zinreich Modification of Lund-Mackay Staging System Total Score

    Zinreich modified the LM system by creating subdivisions within "partial opacification" and increasing the range of scores to 0-5 based on percent opacification: 0 = 0%, 1 = 1%-25%, 2 = 26%-50%, 3 = 51%-75%, 4 = 76%- 99%, and 5 = 100% for each each of 10 sinus cavities (left and right maxillary, anterior ethmoid, posterior ethmoid, sphenoid, and frontal). Total score ranges from 0 to 50.

    Time frame: Baseline, Week 24

  17. Change From Baseline to Week 24/ET in the Zinreich Modification of Lund-Mackay Staging System for the Sinus Pairs.

    Zinreich Modification of the Lund-Mackay Staging System: Zinreich modified the LM system by creating subdivisions within "partial opacification" and increasing the range of scores to 0-5 based on percent opacification: 0 = 0%, 1 = 1%-25%, 2 = 26%-50%, 3 = 51%-75%, 4 = 76%- 99%, and 5 = 100%. Each of the following sinus pairs can achieve a total score of 0-10 (sum of score on each left and right side): anterior ethmoids, posterior ethmoids, maxillary sinuses, frontal sinuses, sphenoid sinuses. The values reported for this outcome are calculated by subtracting the score at baseline from the score at Visit 6 (Wk 24).

    Time frame: Baseline, Week 24

  18. Change From Baseline to Week 24/ET in the Zinreich Modification of Lund-Mackay Staging System for Ethmoids and Maxillary Sinuses Combined

    Zinreich Modification of the Lund-Mackay Staging System: Zinreich modified the LM system by creating subdivisions with "partial opacification" and increasing the range of scores to 0-5 based on percent opacification: 0=0%, 1=1%-25%, 2=26%-50%, 3=51%-75%, 4=76%-99%, and 5=100%. The total score for the combined ethmoids and maxillary sinuses can range from 0-30 (0-5 for each left and right of the anterior ethmoid, posterior ethmoid, and maxillary sinuses). The outcome values presented in the results were determined by subtracting the total score at Baseline from the total score at Week 24.

    Time frame: 24 weeks

  19. Change From Baseline to Week 24/ET in the Zinreich Modification of Lund-Mackay Staging System for the Worst Sinus Between Maxillary and Ethmoid Sinuses Among Patient Populations

    Zinreich Modification of the Lund-Mackay Staging System: Zinreich modified the LM system by creating subdivisions with "partial opacification" and increasing the range of scores to 0-5 based on percent opacification: 0=0%, 1=1%-25%, 2=26%-50%, 3=51%-75%, 4=76%-99%, and 5=100%. Data provided for full population and with and without prior sinus surgery subgroups. Number of participants analyzed in the subgroups will be less than the total overall, as these are only portions of the total population.

    Time frame: 24 Weeks

  20. Change in Sleep Quality as Measured by the Pittsburgh Sleep Quality Index (PSQI)

    The PSQI is a validated, self-rated questionnaire which assesses sleep quality and disturbances over a 1-month time interval. Nineteen individual items generate 7 "component" scores (each ranging between 0 and 3): subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction. The sum of scores for these 7 components yields 1 global score ranging between 0 and 21. Higher values represent a worse outcome.

    Time frame: 12 Weeks, 24 Weeks

  21. Change in Overall Health From Baseline to Week 4 and Week 24/ET as Measured by the Percent of Subjects Improved as Indicated by the Patient Global Impression of Change (PGIC)

    Global impression of change will be assessed using a subject-completed PGIC scale range: 1 - Very much improved, 2 - Much improved, 3 - Minimally improved, 4 - No change, 5 - Minimally worse, 6 - Much worse, 7 - Very much worse. Values provided for this outcome measure are the percentage of subjects reporting a score of 1 - Very much improved, 2 - Much improved, or 3 - Minimally improved at each timepoint.

    Time frame: Week 4, Week 24

  22. Change in Baseline to Week 24/ET as Measured by the Short-Form 36 Health Survey, Version 2 (SF-36v2)

    The SF-36v2 is a multipurpose, 36-item subject-completed validated questionnaire that measures 8 domains of health: physical functioning, role limitations due to physical health (RP), bodily pain, general health perceptions, vitality, social functioning, role limitations due to emotional problems, and mental health. The SF-36v2 survey with a 4-week recall will be used. It yields scale scores for each of these 8 health domains , each of which is scored from 0 to 100. Higher scores indicate a better health status, with 100 representing the highest level of functioning possible.

    Time frame: 24 Weeks

  23. Change in the 36-Item Short Form Health Survey Version 2 (SF-36v2) Mental Component Score (MCS).

    Change from baseline to Week 24/ET on the MCS of the 36-Item Short Form Health Survey version 2 (SF-36v2). The SF-36v2 is a multipurpose, scaled, 36-item, subject-completed validated questionnaire. The scale range is from 0-100. A lower score means more disability and a higher score means less disability. Result values are calculated by subtracting the score reported at Week 24 from the score reported at Baseline.

    Time frame: 24 Weeks

  24. Change in the SF-36v2 Physical Component Score (PCS)

    Change from baseline to Week 24/ET on the PCS of the 36-Item Short Form Health Survey version 2 (SF-36v2). The SF-36v2 is a multipurpose, scaled, 36-item, subject-completed validated questionnaire. The scale range is from 0-100. A lower score means more disability and a higher score means less disability. Result values are calculated by subtracting the score reported at Week 24 from the score reported at Baseline.

    Time frame: 24 Weeks

  25. Change in Depressive Symptoms From Baseline to Week 24/ET as Measured by Change in the Severity of Depression as Measured by the Quick Inventory of Depression Symptomatology (QIDS)

    The 16-item QIDS (Rush et al. 2003) is designed to assess the severity of depressive symptoms. The QIDS is available in a self-rated version and assesses all the criterion symptom domains designated by the American Psychiatry Association Diagnostic and Statistical Manual of Mental Disorders - 5th edition to diagnose a major depressive episode. The 7-day period prior to assessment is the usual time frame for assessing symptom severity. Scores range from 0 to 27, where higher scores indicate a worse outcome.

    Time frame: 24 Weeks

  26. Severity of Depression at Week 24 as Measured by the Quick Inventory of Depression Symptomatology (QIDS)

    The 16-item QIDS (Rush et al. 2003) is designed to assess the severity of depressive symptoms. The QIDS is available in a self-rated version and assesses all the criterion symptom domains designated by the American Psychiatry Association Diagnostic and Statistical Manual of Mental Disorders - 5th edition to diagnose a major depressive episode. The 7-day period prior to assessment is the usual time frame for assessing symptom severity. Scores range from 0 to 27, where higher scores indicate a worse outcome. Results reported for this outcome measure are the

    Time frame: 24 Weeks

  27. Change in Olfactory Impairment From Baseline to Week 24/ET as Measured by the Smell Identification Test (SIT)™

    The SIT is a test comprised of 4 booklets each containing 10 microencapsulated (scratch and sniff) odors. Forced choice response alternatives accompany each test item. Each correct response is assigned a score of 1 and incorrect responses are assigned a score of 0. The total score is calculated by summing the scores of each individual odor for a total possible score ranging from 0-40. The higher the score, the better the individual's sense of smell. The test provides an absolute indication of smell loss (anosmia; mild, moderate or sever hyposmia) as well as an index to detect malingering.

    Time frame: 24 Weeks

  28. Change in Baseline to Week 24/ET as Measured by the Euroqol 5-dimension (EQ-5D) Instrument

    The EQ-5D consists of the EQ-5D descriptive system and the EQ visual analogue scale (EQ VAS). The outcome measured for this study was the EQ VAS, which records the subject's self-rated health on a vertical visual analogue scale, where the endpoints are labelled "The best health you can imagine" and "The worst health you can imagine". The VAS can be used as a quantitative measure of health outcome that reflects the subject's own judgement. VAS scores range from 0 (worst health you can imagine) to 100 (best health you can imagine).

    Time frame: 24 Weeks

  29. Change in Baseline to Week 24/ET as Measured by the Short-Form 6-Dimension (SF-6D) Instrument

    The SF-6D is a single health state index derived from the 11 items from the SF-36v2. SF-6D scores range from 0 (worst health state) to 1 (best health state). The values provided in the outcome data are calculated by subtracting the score reported at baseline from the score reported at Visit 6 (Week 24).

    Time frame: 24 Weeks

  30. Percentage of Subjects Indicating That They Are Willing to Consider Sinus Surgery at Baseline and Week 24

    Percentage of subjects indicating that they are willing to consider Sinus Surgery. This is a comparison of health economic measures and data was obtained by direct questioning of the subjects during study visits.

    Time frame: Baseline, Week 24

  31. Percentage of Subjects Who Meet the Minimal Objective Criteria for Surgical Intervention at Baseline and Week 24.

    Percentage of subjects who meet the minimal objective criteria for surgical intervention based on completion of a surgical intervention assessment questionnaire for the investigator.

    Time frame: Baseline, Week 24

  32. Percentage of Subjects Approved for Surgery Who no Longer Elect to Undergo a Surgery

    Outcome value presented here is the percent of subjects who are approved for surgery but no longer elect to undergo a surgery. Number of participants analyzed indicates the total number of participants for whom this analysis was completed.

    Time frame: Week 24

Other outcomes

  1. Evaluation of Safety by Recording the Severity of Adverse Events (AEs)

    Assessment of safety by measuring severity of AEs using scale with 1=mild, 2=moderate, 3=severe

    Time frame: 24 Weeks

  2. Evaluation of Safety-Nasal Examination

    Assessed in nasal examination worksheet which includes recording the presence of any epistaxis, septal erosion/perforation, ulceration/erosion of area other than septum.

    Time frame: 24 Weeks

  3. Evaluation of Safety Measuring Vital Signs- Blood Pressure

    Includes systolic and diastolic blood pressure measurements in millimeter of mercury (mmHg)

    Time frame: 24 Weeks

  4. Evaluation of Safety Measuring Vital Signs- Pulse

    Measure pulse in beats per minute (bpm)

    Time frame: 24 Weeks

  5. Evaluation of Safety Measuring Vital Signs- Weight

    Assessment of safety from physical examination-weight measured in kg or lb

    Time frame: 24 Weeks

  6. Evaluation of Safety - Monitoring Concomitant Medication Usage

    Assessment for safety from the collection of information for concomitant medications usage. Top 5 reported con-meds by therapeutic class are listed for this outcome.

    Time frame: 24 Weeks

07

Results

Posted Dec 21, 2023

Participant flow

Participant flow — Overall Study
MilestonePlaceboOPN-375 186 μg BIDOPN-375 372 μg BID
Started757474
Completed697071
Not completed643
Withdrew: Adverse event211
Withdrew: Lost to follow-up100
Withdrew: Lack of efficacy210
Withdrew: Protocol violation001
Withdrew: Withdrawal by subject111
Withdrew: Marked randomized in error (patient did not receive study drug)010

Outcome measures

PrimaryChange From Baseline in Symptoms as Measured by a Composite Score for Each Symptom of Nasal Congestion, Facial Pain or Pressure Sensation, and Nasal Discharge (Anterior and/or Posterior) at the End of Week 4

Change from baseline to the end of Week 4 in average total instantaneous AM scores (evaluation of symptom severity immediately preceding the time of scoring) for each symptom: nasal congestion, nasal discharge (anterior and/or posterior), facial pain/pressure sensation. Baseline scores are the averaged total instantaneous AM scores over the last 7 days of the single blind run in period, and the end of Week 4, scores are averaged over the 7 days from the subject diary. Range of scores for each nasal symptom is 0= none, 1 = mild, 2 = moderate, 3 = severe. Composite score is a sum of the 3 symptom scores and will range from 0 to 9.

Time frame:
4 Weeks
Reported as:
Least squares mean · score on a scale
Change From Baseline in Symptoms as Measured by a Composite Score for Each Symptom of Nasal Congestion, Facial Pain or Pressure Sensation, and Nasal Discharge (Anterior and/or Posterior) at the End of Week 4
score on a scalePlaceboOPN-375 186 μg BIDOPN-375 372 μg BID
Change From Baseline in Symptoms as Measured by a Composite Score for Each Symptom of Nasal Congestion, Facial Pain or Pressure Sensation, and Nasal Discharge (Anterior and/or Posterior) at the End of Week 4-0.81 ± 0.202-1.54 ± 0.204-1.74 ± 0.204
PrimaryChange From Baseline to Week 24/Early Termination (ET) in the Average Percent of the Volume Opacified (APOV) in the Ethmoid and Maxillary Sinuses.

Change from baseline to Week 24/ET in the average percent of ethmoid and maxillary sinus volume opacified as measured by CT. Percent volume opacified can range from 0% to 100%. Outcome measure is the percentage change from percent opacification at baseline to percent opacification at Week 24; therefore, change in opacification volume can range from -100% to 100%. For example, if Baseline opacification was 68.22% and Week 24 opacification was 66.11%, then the change would be reported as -2.11%.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · percentage of opacification
Change From Baseline to Week 24/Early Termination (ET) in the Average Percent of the Volume Opacified (APOV) in the Ethmoid and Maxillary Sinuses.
percentage of opacificationPlaceboOPN-375 186 μg BIDOPN-375 372 μg BID
Change From Baseline to Week 24/Early Termination (ET) in the Average Percent of the Volume Opacified (APOV) in the Ethmoid and Maxillary Sinuses.1.19 ± 1.740-7.00 ± 1.725-5.14 ± 1.742
SecondaryChange From Baseline to Week 4 in Each of the 4 Individual Cardinal Chronic Rhinosinusitis (CRS) Symptoms (AM, Instantaneous).

The 4 individual CRS symptoms are: congestion, facial pain or pressure sensation, nasal discharge (anterior and/or posterior), and sense of smell. Range of scores for each nasal symptom is 0= none, 1 = mild, 2 = moderate, 3 = severe. The scores at baseline and week 4 are calculated by averaging the score reported for the individual symptom over 7 days prior to the timepoint. The value provided in the results is calculated by subtracting the score at Week 4 from the score at Baseline; therefore, scores reported here can range from -3 to 3.

Time frame:
Baseline, Week 4
Reported as:
Least squares mean · score on a scale
Change From Baseline to Week 4 in Each of the 4 Individual Cardinal Chronic Rhinosinusitis (CRS) Symptoms (AM, Instantaneous).
score on a scalePlaceboOPN-375 186 μg BIDOPN-375 372 μg BID
Congestion/Obstruction-0.26 ± 0.076-0.60 ± 0.077-0.70 ± 0.077
Nasal Discharge-0.27 ± 0.076-0.52 ± 0.076-0.55 ± 0.077
Facial Pain/Pressure-0.28 ± 0.080-0.44 ± 0.081-0.51 ± 0.081
Sense of Smell-0.13 ± 0.066-0.24 ± 0.067-0.36 ± 0.067
SecondaryTime to First Acute Exacerbation of Chronic Sinusitis

Comparing the distribution of time to first acute exacerbation of chronic sinusitis across treatment groups. An exacerbation of chronic sinusitis is defined as a worsening of symptoms that requires escalation of treatment.

Time frame:
24 Weeks
Reported as:
Mean · Weeks
Time to First Acute Exacerbation of Chronic Sinusitis
WeeksPlaceboOPN-375 186 μg BIDOPN-375 372 μg BID
Time to First Acute Exacerbation of Chronic Sinusitis9.83 ± 0.2155.00 ± 08.04 ± 0.131
SecondaryChange From Baseline to Defined Timepoints - Subject Symptoms and Functioning as Measured by the Sinonasal Outcome Test - 22-item (SNOT-22) Total Score and Sub Domains

The SNOT-22 is a subject-completed questionnaire that consists of 22 symptoms and social/emotional consequences of their nasal disorder across several domains including: rhinologic, extra-nasal rhinologic, ear/facial pain, psychological dysfunction, and sleep dysfunction. Total scores range from 0-110. The score range for each domain are as follows: Rhinologic: 0-30; Extra-nasal rhinologic: 0-15; Ear/facial: 0-25; Psychological dysfunction: 0-35; Sleep dysfunction: 0-25. Each item is rated as follows: 0=no problem, 1=very mild problem, 2=mild or slight problem, 3=moderate problem, 4=severe problem, 5=problem as bad as it can be, and total scores are calculated by adding scores together. The values reported here are calculated by subtracting the score reported at baseline from the score reported at Week 24 and, therefore, can range from the negative maximum score value to the positive maximum score value.

Time frame:
24 Weeks
Reported as:
Least squares mean · score on a scale
Change From Baseline to Defined Timepoints - Subject Symptoms and Functioning as Measured by the Sinonasal Outcome Test - 22-item (SNOT-22) Total Score and Sub Domains
score on a scalePlaceboOPN-375 186 μg BIDOPN-375 372 μg BID
Total Score-8.72 ± 2.186-19.45 ± 2.197-15.54 ± 2.219
Rhinologic Symptoms Domain Score-2.47 ± 0.649-5.25 ± 0.653-4.77 ± 0.656
Extra-Nasal Rhinologic Symptoms Domain Score-1.61 ± 0.411-2.84 ± 0.413-2.45 ± 0.415
Ear/Facial Symptoms Domain Score-1.31 ± 0.613-4.45 ± 0.616-3.18 ± 0.619
Psychological Dysfunction Domain Score-1.80 ± 0.951-5.81 ± 0.955-4.16 ± 0.965
Sleep Dysfunction Domain Score-1.77 ± 0.620-4.84 ± 0.622-3.61 ± 0.626
SecondaryChange From Baseline to Week 8 and 12 in Composite Symptom Score (Congestion, Facial Pain or Pressure Sensation, and Nasal Discharge) for the Total Population and Patients With and Without Previous Sinus Surgery.

Change from baseline in average total instantaneous AM scores (evaluation of symptom severity immediately preceding the time of scoring) for each symptom: nasal congestion, nasal discharge (anterior and/or posterior), facial pain/pressure sensation. Range of scores for each symptom is 0=none, 1=mild, 2=moderate, 3=severe. The composite score is the sum of the 3 symptom scores and will range from 0-9. Scores reported at each timepoint are the averaged total instantaneous AM scores over the last 7 days before the given timepoint. The values presented here are calculated by subtracting the score at Baseline from Week 8 and Week 12, respectively.

Time frame:
8 weeks, 12 weeks.
Reported as:
Least squares mean · score on a scale
Change From Baseline to Week 8 and 12 in Composite Symptom Score (Congestion, Facial Pain or Pressure Sensation, and Nasal Discharge) for the Total Population and Patients With and Without Previous Sinus Surgery.
score on a scalePlaceboOPN-375 186 μg BIDOPN-375 372 μg BID
Week 8 Change Total Population-1.20 ± 0.210-2.02 ± 0.212-2.19 ± 0.212
Week 12 Change Total Population-1.55 ± 0.220-2.47 ± 0.223-2.60 ± 0.223
Week 8 Change With Prior Surgery Population-1.28 ± 0.347-2.28 ± 0.355-1.95 ± 0.355
Week 12 Change With Prior Surgery Population-1.58 ± 0.361-2.76 ± 0.379-2.36 ± 0.375
Week 8 Change Without Prior Surgery Population-1.13 ± 0.263-1.86 ± 0.260-2.28 ± 0.260
Week 12 Change Without Prior Surgery Population-1.51 ± 0.276-2.30 ± 0.273-2.70 ± 0.274
SecondaryChange From Baseline to Weeks 8 and 12 in Nasal Congestion Measured by Instantaneous Morning (AM) and Evening (PM) Diary Symptom Scores

Subjects will report instantaneous (evaluation of symptom severity immediately preceding the time of scoring) symptoms. The Nasal Symptom Scale scores as 0=none, 1=mild-symptoms clearly present but minimal awareness, and easily tolerated, 2= moderate - definite awareness of symptoms that is bothersome but tolerable, 3 = severe - symptoms that are hard to tolerate, cause interference with activities or daily living.

Time frame:
8 Weeks; 12 Weeks
Reported as:
Least squares mean · score on a scale
Change From Baseline to Weeks 8 and 12 in Nasal Congestion Measured by Instantaneous Morning (AM) and Evening (PM) Diary Symptom Scores
score on a scalePlaceboOPN-375 186 μg BIDOPN-375 372 μg BID
Change in AM Score - Week 8-0.40 ± 0.078-0.76 ± 0.079-0.84 ± 0.079
Change in PM Score - Week 8-0.35 ± 0.081-0.69 ± 0.082-0.75 ± 0.082
Change in AM Score - Week 12-0.52 ± 0.081-0.88 ± 0.082-0.97 ± 0.082
Change in PM Score - Week 12-0.50 ± 0.080-0.85 ± 0.081-0.91 ± 0.082
SecondaryChange From Baseline to Weeks 8 and 12 in Nasal Discharge (Anterior and/or Posterior) Measured by Instantaneous AM and PM Diary Symptom Scores

Subjects will report instantaneous (evaluation of symptom severity immediately preceding the time of scoring) scores. The Nasal Symptom Scale scores as 0=none, 1=mild-symptoms clearly present but minimal awareness, and easily tolerated, 2= moderate - definite awareness of symptoms that is bothersome but tolerable, 3 = severe - symptoms that are hard to tolerate, cause interference with activities or daily living

Time frame:
Baseline, Week 8, Week 12
Reported as:
Least squares mean · score on a scale
Change From Baseline to Weeks 8 and 12 in Nasal Discharge (Anterior and/or Posterior) Measured by Instantaneous AM and PM Diary Symptom Scores
score on a scalePlaceboOPN-375 186 μg BIDOPN-375 372 μg BID
Change in AM Score - Week 8-0.39 ± 0.080-0.63 ± 0.080-0.68 ± 0.080
Change in PM Score - Week 8-0.35 ± 0.081-0.66 ± 0.082-0.68 ± 0.082
Change in AM Score - Week 12-0.49 ± 0.085-0.83 ± 0.086-0.85 ± 0.086
Change in PM Score - Week 12-0.51 ± 0.085-0.83 ± 0.086-0.86 ± 0.087
SecondaryChange From Baseline to Weeks 8 and 12 in Facial Pain or Pressure Sensation Measured by Instantaneous AM and PM Diary Symptom Scores

Subjects will report instantaneous (evaluation of symptom severity immediately preceding the time of scoring) symptoms. The Nasal Symptom Scale scores as 0=none, 1=mild-symptoms clearly present but minimal awareness, and easily tolerated, 2= moderate - definite awareness of symptoms that is bothersome but tolerable, 3 = severe - symptoms that are hard to tolerate, cause interference with activities or daily living.

Time frame:
Baseline, Week 8, Week 12
Reported as:
Least squares mean · score on a scale
Change From Baseline to Weeks 8 and 12 in Facial Pain or Pressure Sensation Measured by Instantaneous AM and PM Diary Symptom Scores
score on a scalePlaceboOPN-375 186 μg BIDOPN-375 372 μg BID
Change in AM Score - Week 8-0.41 ± 0.084-0.63 ± 0.085-0.67 ± 0.085
Change in PM Score - Week 8-0.41 ± 0.085-0.66 ± 0.086-0.70 ± 0.086
Change in AM Score - Week 12-0.55 ± 0.089-0.77 ± 0.090-0.78 ± 0.091
Change in PM Score - Week 12-0.53 ± 0.089-0.77 ± 0.091-0.78 ± 0.091
SecondaryChange From Baseline to Weeks 8 and 12 in Sense of Smell Scores Measured by Instantaneous AM and PM Diary Symptom Scores

Subjects will report instantaneous (evaluation of symptom severity immediately preceding the time of scoring) symptoms. The sense of smell scored as 0= normal, 1=slightly impaired, 2=moderately impaired, 3=absent.

Time frame:
Baseline, Week 8, Week 12
Reported as:
Least squares mean · score on a scale
Change From Baseline to Weeks 8 and 12 in Sense of Smell Scores Measured by Instantaneous AM and PM Diary Symptom Scores
score on a scalePlaceboOPN-375 186 μg BIDOPN-375 372 μg BID
Change in AM Score - Week 8-0.18 ± 0.082-0.39 ± 0.083-0.55 ± 0.083
Change in PM Score - Week 8-0.13 ± 0.081-0.35 ± 0.082-0.51 ± 0.082
Change in AM Score - Week 12-0.32 ± 0.086-0.49 ± 0.087-0.63 ± 0.087
Change in PM Score - Week 12-0.29 ± 0.085-0.46 ± 0.086-0.55 ± 0.086
SecondaryChange From Baseline to Week 24/ET in the Average Percent of the Volume Opacified in the Ethmoid and Maxillary Sinuses for Patients With and Without Previous Sinus Surgery

Change from Baseline to Week 24/ET in the average percent of ethmoid and maxillary sinus volume opacified as measured by CT for subgroups in patients without and without previous sinus surgery. Percent volume opacified of the combined ethmoid and maxillary sinuses can range from 0% to 100%. Outcome measure is percentage change from percent opacification at baseline to percent opacification at Week 24; therefore, change in opacification volume can range from -100% to 100%. For example, if Baseline opacification was 68.22% and Week 24 opacification was 66.11%, then the change would be reported as -2.11%.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · percentage of opacification
Change From Baseline to Week 24/ET in the Average Percent of the Volume Opacified in the Ethmoid and Maxillary Sinuses for Patients With and Without Previous Sinus Surgery
percentage of opacificationPlaceboOPN-375 186 μg BIDOPN-375 372 μg BID
Patients with prior sinus surgery3.89 ± 2.882-5.86 ± 2.862-6.73 ± 2.873
Patients without prior sinus surgery-0.53 ± 2.118-7.83 ± 2.129-4.50 ± 2.166
SecondaryChange From Baseline to Week 24/ET in the Lund-Mackay Staging System Total Score

Lund-Mackay Staging System: Lund-Mackay (LM) system (Lund and Mackay, 1993) assigns to each of 10 sinus cavities (left and right maxillary, anterior ethmoid, posterior ethmoid, sphenoid, and frontal) a score of 0 (no opacification), 1 (partial opacification), or 2 (total opacification), plus a 0-2 score for each of the left and right ostiomeatal complex (OMC). The total LM score for a CT scan ranges from 0-24.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · score on a scale
Change From Baseline to Week 24/ET in the Lund-Mackay Staging System Total Score
score on a scalePlaceboOPN-375 186 μg BIDOPN-375 372 μg BID
Change From Baseline to Week 24/ET in the Lund-Mackay Staging System Total Score0.77 ± 0.332-0.54 ± 0.327-0.33 ± 0.329
SecondaryChange From Baseline to Week24/ET in the Lund-Mackay Staging System Scores for Each Sinus Pair

Lund-Mackay Staging System: Lund-Mackay (LM) system (Lund and Mackay, 1993) assigns to each of 10 sinus cavities (left and right maxillary, anterior ethmoid, posterior ethmoid, sphenoid, and frontal) a score of 0 (no opacification), 1 (partial opacification), or 2 (total opacification). Each sinus pair (left and right side) listed below can achieve a total score of 0-4 (sum of 0-2 for each side). The values reported below are calculated by subtracting the total score at baseline from the total score at Visit 6 (week 24).

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · score on a scale
Change From Baseline to Week24/ET in the Lund-Mackay Staging System Scores for Each Sinus Pair
score on a scalePlaceboOPN-375 186 μg BIDOPN-375 372 μg BID
Anterior Ethmoid Pair0.17 ± 0.0710.03 ± 0.0710.02 ± 0.071
Posterior Ethmoid Pair0.11 ± 0.0710.04 ± 0.071-0.04 ± 0.071
Maxillary Sinus Pair0.04 ± 0.0520.01 ± 0.0490.09 ± 0.049
Frontal Sinus Pair0.11 ± 0.093-0.12 ± 0.091-0.03 ± 0.092
Sphenoid Sinus Pair0.19 ± 0.078-0.04 ± 0.0770.03 ± 0.078
SecondaryChange From Baseline to Week 24/ET in the Average Percent of Sinus Volume Occupied by Disease in the Worst Maxillary Sinus, as Measured by CT Scan Assessment.

Percent volume opacified of the worst maxillary sinus can range from 0% to 100%. The outcome measure is the percentage change from percent opacification of the worst maxillary sinus at baseline to the percent opacification of the same maxillary sinus at Week 24; therefore, change in opacification volume can range from -100% to 100%.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · percentage of opacification
Change From Baseline to Week 24/ET in the Average Percent of Sinus Volume Occupied by Disease in the Worst Maxillary Sinus, as Measured by CT Scan Assessment.
percentage of opacificationPlaceboOPN-375 186 μg BIDOPN-375 372 μg BID
Change From Baseline to Week 24/ET in the Average Percent of Sinus Volume Occupied by Disease in the Worst Maxillary Sinus, as Measured by CT Scan Assessment.-5.83 ± 2.734-14.50 ± 2.708-10.21 ± 2.724
SecondaryChange From Baseline to Week 24/ET in the Average Percent of Sinus Volume Occupied by Disease in the Worst Ethmoid Sinus, as Measured by CT Scan Assessment.

Percent volume opacified of the worst ethmoid sinus can range from 0% to 100%. The outcome measure is the percentage change from percent opacification of the worst ethmoid sinus at baseline to the percent opacification of the same ethmoid sinus at Week 24; therefore, change in opacification volume can range from -100% to 100%.

Time frame:
24 weeks
Reported as:
Least squares mean · percentage of opacification
Change From Baseline to Week 24/ET in the Average Percent of Sinus Volume Occupied by Disease in the Worst Ethmoid Sinus, as Measured by CT Scan Assessment.
percentage of opacificationPlaceboOPN-375 186 μg BIDOPN-375 372 μg BID
Change From Baseline to Week 24/ET in the Average Percent of Sinus Volume Occupied by Disease in the Worst Ethmoid Sinus, as Measured by CT Scan Assessment.-2.79 ± 1.928-9.65 ± 1.920-6.82 ± 1.928
SecondaryChange From Baseline to Week 24/ET in the Average Percent of Sinus Volume Occupied by Disease in the Worst Sinus Between Maxillary and Ethmoid Sinuses, as Measured by CT Scan Assessment.

Percent volume opacified of the worst sinus can range from 0% to 100%. The outcome measure is the percentage change from percent opacification of the worst sinus at baseline to the percent opacification of the same sinus at Week 24; therefore, change in opacification volume can range from -100% to 100%.

Time frame:
24 weeks
Reported as:
Least squares mean · percentage of opacification
Change From Baseline to Week 24/ET in the Average Percent of Sinus Volume Occupied by Disease in the Worst Sinus Between Maxillary and Ethmoid Sinuses, as Measured by CT Scan Assessment.
percentage of opacificationPlaceboOPN-375 186 μg BIDOPN-375 372 μg BID
Change From Baseline to Week 24/ET in the Average Percent of Sinus Volume Occupied by Disease in the Worst Sinus Between Maxillary and Ethmoid Sinuses, as Measured by CT Scan Assessment.-6.07 ± 2.493-14.02 ± 2.439-10.75 ± 2.448
SecondaryChange From Baseline to Week24/ET in the Lund-Mackay Staging System Scores for the Ethmoids and Maxillary Sinuses Combined

Lund-Mackay Staging System: Lund-Mackay (LM) system (Lund and Mackay, 1993) assigns to each of 10 sinus cavities (left and right maxillary, anterior ethmoid, posterior ethmoid, sphenoid, and frontal) a score of 0 (no opacification), 1 (partial opacification), or 2 (total opacification), plus a 0-2 score for each of the left and right ostiomeatal complex (OMC). The values reported for this outcome are the change in total opacification of the left an dright maxillary and ethmoid sinuses (Visit 6 \[Wk 24\] score minus Baseline score). Each visit score can range from a total of 0-12 (sum of 0-2 score assigned for each of left and right maxillary, left and right anterior ethmoid, and left and right posterior ethmoid).

Time frame:
24 Weeks
Reported as:
Least squares mean · score on a scale
Change From Baseline to Week24/ET in the Lund-Mackay Staging System Scores for the Ethmoids and Maxillary Sinuses Combined
score on a scalePlaceboOPN-375 186 μg BIDOPN-375 372 μg BID
Change From Baseline to Week24/ET in the Lund-Mackay Staging System Scores for the Ethmoids and Maxillary Sinuses Combined0.34 ± 0.1620.09 ± 0.1600.04 ± 0.160
SecondaryChange From Baseline to Week 24/ET in the Zinreich Modification of Lund-Mackay Staging System Total Score

Zinreich modified the LM system by creating subdivisions within "partial opacification" and increasing the range of scores to 0-5 based on percent opacification: 0 = 0%, 1 = 1%-25%, 2 = 26%-50%, 3 = 51%-75%, 4 = 76%- 99%, and 5 = 100% for each each of 10 sinus cavities (left and right maxillary, anterior ethmoid, posterior ethmoid, sphenoid, and frontal). Total score ranges from 0 to 50.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · score on a scale
Change From Baseline to Week 24/ET in the Zinreich Modification of Lund-Mackay Staging System Total Score
score on a scalePlaceboOPN-375 186 μg BIDOPN-375 372 μg BID
Change From Baseline to Week 24/ET in the Zinreich Modification of Lund-Mackay Staging System Total Score0.73 ± 0.815-2.44 ± 0.806-1.45 ± 0.816
SecondaryChange From Baseline to Week 24/ET in the Zinreich Modification of Lund-Mackay Staging System for the Sinus Pairs.

Zinreich Modification of the Lund-Mackay Staging System: Zinreich modified the LM system by creating subdivisions within "partial opacification" and increasing the range of scores to 0-5 based on percent opacification: 0 = 0%, 1 = 1%-25%, 2 = 26%-50%, 3 = 51%-75%, 4 = 76%- 99%, and 5 = 100%. Each of the following sinus pairs can achieve a total score of 0-10 (sum of score on each left and right side): anterior ethmoids, posterior ethmoids, maxillary sinuses, frontal sinuses, sphenoid sinuses. The values reported for this outcome are calculated by subtracting the score at baseline from the score at Visit 6 (Wk 24).

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · score on a scale
Change From Baseline to Week 24/ET in the Zinreich Modification of Lund-Mackay Staging System for the Sinus Pairs.
score on a scalePlaceboOPN-375 186 μg BIDOPN-375 372 μg BID
Anterior Ethmoid Sinus Pair0.18 ± 0.218-0.73 ± 0.215-0.48 ± 0.217
Posterior Ethmoid Sinus Pair0.18 ± 0.239-0.54 ± 0.234-0.41 ± 0.236
Maxillary Sinus Pair0.17 ± 0.200-0.54 ± 0.200-0.36 ± 0.202
Frontal Sinus Pair0.11 ± 0.250-0.37 ± 0.2450.00 ± 0.246
Sphenoid Sinus Pair0.46 ± 0.249-0.32 ± 0.2390.02 ± 0.243
SecondaryChange From Baseline to Week 24/ET in the Zinreich Modification of Lund-Mackay Staging System for Ethmoids and Maxillary Sinuses Combined

Zinreich Modification of the Lund-Mackay Staging System: Zinreich modified the LM system by creating subdivisions with "partial opacification" and increasing the range of scores to 0-5 based on percent opacification: 0=0%, 1=1%-25%, 2=26%-50%, 3=51%-75%, 4=76%-99%, and 5=100%. The total score for the combined ethmoids and maxillary sinuses can range from 0-30 (0-5 for each left and right of the anterior ethmoid, posterior ethmoid, and maxillary sinuses). The outcome values presented in the results were determined by subtracting the total score at Baseline from the total score at Week 24.

Time frame:
24 weeks
Reported as:
Least squares mean · score on a scale
Change From Baseline to Week 24/ET in the Zinreich Modification of Lund-Mackay Staging System for Ethmoids and Maxillary Sinuses Combined
score on a scalePlaceboOPN-375 186 μg BIDOPN-375 372 μg BID
Change From Baseline to Week 24/ET in the Zinreich Modification of Lund-Mackay Staging System for Ethmoids and Maxillary Sinuses Combined0.51 ± 0.568-1.78 ± 0.540-1.25 ± 0.546
SecondaryChange From Baseline to Week 24/ET in the Zinreich Modification of Lund-Mackay Staging System for the Worst Sinus Between Maxillary and Ethmoid Sinuses Among Patient Populations

Zinreich Modification of the Lund-Mackay Staging System: Zinreich modified the LM system by creating subdivisions with "partial opacification" and increasing the range of scores to 0-5 based on percent opacification: 0=0%, 1=1%-25%, 2=26%-50%, 3=51%-75%, 4=76%-99%, and 5=100%. Data provided for full population and with and without prior sinus surgery subgroups. Number of participants analyzed in the subgroups will be less than the total overall, as these are only portions of the total population.

Time frame:
24 Weeks
Reported as:
Least squares mean · score on a scale
Change From Baseline to Week 24/ET in the Zinreich Modification of Lund-Mackay Staging System for the Worst Sinus Between Maxillary and Ethmoid Sinuses Among Patient Populations
score on a scalePlaceboOPN-375 186 μg BIDOPN-375 372 μg BID
Total population-0.36 ± 0.137-0.93 ± 0.135-0.55 ± 0.135
Prior sinus surgery subgroup-0.37 ± 0.228-0.70 ± 0.223-0.64 ± 0.225
Without prior sinus surgery subgroup-0.37 ± 0.165-1.06 ± 0.167-0.52 ± 0.168
SecondaryChange in Sleep Quality as Measured by the Pittsburgh Sleep Quality Index (PSQI)

The PSQI is a validated, self-rated questionnaire which assesses sleep quality and disturbances over a 1-month time interval. Nineteen individual items generate 7 "component" scores (each ranging between 0 and 3): subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction. The sum of scores for these 7 components yields 1 global score ranging between 0 and 21. Higher values represent a worse outcome.

Time frame:
12 Weeks, 24 Weeks
Reported as:
Least squares mean · score on a scale
Change in Sleep Quality as Measured by the Pittsburgh Sleep Quality Index (PSQI)
score on a scalePlaceboOPN-375 186 μg BIDOPN-375 372 μg BID
Week 12-0.27 ± 0.306-1.18 ± 0.310-1.12 ± 0.307
Week 24-0.33 ± 0.293-2.01 ± 0.298-1.08 ± 0.295
SecondaryChange in Overall Health From Baseline to Week 4 and Week 24/ET as Measured by the Percent of Subjects Improved as Indicated by the Patient Global Impression of Change (PGIC)

Global impression of change will be assessed using a subject-completed PGIC scale range: 1 - Very much improved, 2 - Much improved, 3 - Minimally improved, 4 - No change, 5 - Minimally worse, 6 - Much worse, 7 - Very much worse. Values provided for this outcome measure are the percentage of subjects reporting a score of 1 - Very much improved, 2 - Much improved, or 3 - Minimally improved at each timepoint.

Time frame:
Week 4, Week 24
Reported as:
Count of participants · Participants
Change in Overall Health From Baseline to Week 4 and Week 24/ET as Measured by the Percent of Subjects Improved as Indicated by the Patient Global Impression of Change (PGIC)
ParticipantsPlaceboOPN-375 186 μg BIDOPN-375 372 μg BID
Week 4374756
Week 24425963
SecondaryChange in Baseline to Week 24/ET as Measured by the Short-Form 36 Health Survey, Version 2 (SF-36v2)

The SF-36v2 is a multipurpose, 36-item subject-completed validated questionnaire that measures 8 domains of health: physical functioning, role limitations due to physical health (RP), bodily pain, general health perceptions, vitality, social functioning, role limitations due to emotional problems, and mental health. The SF-36v2 survey with a 4-week recall will be used. It yields scale scores for each of these 8 health domains , each of which is scored from 0 to 100. Higher scores indicate a better health status, with 100 representing the highest level of functioning possible.

Time frame:
24 Weeks
Reported as:
Least squares mean · score on a scale
Change in Baseline to Week 24/ET as Measured by the Short-Form 36 Health Survey, Version 2 (SF-36v2)
score on a scalePlaceboOPN-375 186 μg BIDOPN-375 372 μg BID
Physical Functioning Score0.54 ± 1.0123.46 ± 1.0232.24 ± 1.043
Role Physical Score0.18 ± 1.0185.02 ± 1.0293.73 ± 1.049
Bodily Pain Score2.46 ± 1.1935.74 ± 1.2053.54 ± 1.223
General Health Score-0.20 ± 1.0104.71 ± 1.0252.78 ± 1.037
Vitality Score0.35 ± 1.1204.59 ± 1.1293.98 ± 1.157
Social Functioning Score-0.11 ± 1.1734.70 ± 1.1861.58 ± 1.204
Role Emotional Score-0.77 ± 1.1332.23 ± 1.1470.42 ± 1.167
Mental Health score-1.70 ± 1.1002.26 ± 1.1121.23 ± 1.138
SecondaryChange in the 36-Item Short Form Health Survey Version 2 (SF-36v2) Mental Component Score (MCS).

Change from baseline to Week 24/ET on the MCS of the 36-Item Short Form Health Survey version 2 (SF-36v2). The SF-36v2 is a multipurpose, scaled, 36-item, subject-completed validated questionnaire. The scale range is from 0-100. A lower score means more disability and a higher score means less disability. Result values are calculated by subtracting the score reported at Week 24 from the score reported at Baseline.

Time frame:
24 Weeks
Reported as:
Least squares mean · score on a scale
Change in the 36-Item Short Form Health Survey Version 2 (SF-36v2) Mental Component Score (MCS).
score on a scalePlaceboOPN-375 186 μg BIDOPN-375 372 μg BID
Change in the 36-Item Short Form Health Survey Version 2 (SF-36v2) Mental Component Score (MCS).-0.82 ± 0.8882.25 ± 0.8951.17 ± 0.913
SecondaryChange in the SF-36v2 Physical Component Score (PCS)

Change from baseline to Week 24/ET on the PCS of the 36-Item Short Form Health Survey version 2 (SF-36v2). The SF-36v2 is a multipurpose, scaled, 36-item, subject-completed validated questionnaire. The scale range is from 0-100. A lower score means more disability and a higher score means less disability. Result values are calculated by subtracting the score reported at Week 24 from the score reported at Baseline.

Time frame:
24 Weeks
Reported as:
Least squares mean · score on a scale
Change in the SF-36v2 Physical Component Score (PCS)
score on a scalePlaceboOPN-375 186 μg BIDOPN-375 372 μg BID
Change in the SF-36v2 Physical Component Score (PCS)2.12 ± 0.7125.35 ± 0.7234.34 ± 0.738
SecondaryChange in Depressive Symptoms From Baseline to Week 24/ET as Measured by Change in the Severity of Depression as Measured by the Quick Inventory of Depression Symptomatology (QIDS)

The 16-item QIDS (Rush et al. 2003) is designed to assess the severity of depressive symptoms. The QIDS is available in a self-rated version and assesses all the criterion symptom domains designated by the American Psychiatry Association Diagnostic and Statistical Manual of Mental Disorders - 5th edition to diagnose a major depressive episode. The 7-day period prior to assessment is the usual time frame for assessing symptom severity. Scores range from 0 to 27, where higher scores indicate a worse outcome.

Time frame:
24 Weeks
Reported as:
Least squares mean · score on a scale
Change in Depressive Symptoms From Baseline to Week 24/ET as Measured by Change in the Severity of Depression as Measured by the Quick Inventory of Depression Symptomatology (QIDS)
score on a scalePlaceboOPN-375 186 μg BIDOPN-375 372 μg BID
Change in Depressive Symptoms From Baseline to Week 24/ET as Measured by Change in the Severity of Depression as Measured by the Quick Inventory of Depression Symptomatology (QIDS)-0.23 ± 0.306-0.74 ± 0.308-0.20 ± 0.312
SecondarySeverity of Depression at Week 24 as Measured by the Quick Inventory of Depression Symptomatology (QIDS)

The 16-item QIDS (Rush et al. 2003) is designed to assess the severity of depressive symptoms. The QIDS is available in a self-rated version and assesses all the criterion symptom domains designated by the American Psychiatry Association Diagnostic and Statistical Manual of Mental Disorders - 5th edition to diagnose a major depressive episode. The 7-day period prior to assessment is the usual time frame for assessing symptom severity. Scores range from 0 to 27, where higher scores indicate a worse outcome. Results reported for this outcome measure are the

Time frame:
24 Weeks
Reported as:
Count of participants · Participants
Severity of Depression at Week 24 as Measured by the Quick Inventory of Depression Symptomatology (QIDS)
ParticipantsPlaceboOPN-375 186 μg BIDOPN-375 372 μg BID
No depression525551
Mild depression151215
Moderate depression042
Severe depression001
Very severe depression200
SecondaryChange in Olfactory Impairment From Baseline to Week 24/ET as Measured by the Smell Identification Test (SIT)™

The SIT is a test comprised of 4 booklets each containing 10 microencapsulated (scratch and sniff) odors. Forced choice response alternatives accompany each test item. Each correct response is assigned a score of 1 and incorrect responses are assigned a score of 0. The total score is calculated by summing the scores of each individual odor for a total possible score ranging from 0-40. The higher the score, the better the individual's sense of smell. The test provides an absolute indication of smell loss (anosmia; mild, moderate or sever hyposmia) as well as an index to detect malingering.

Time frame:
24 Weeks
Reported as:
Least squares mean · score on a scale
Change in Olfactory Impairment From Baseline to Week 24/ET as Measured by the Smell Identification Test (SIT)™
score on a scalePlaceboOPN-375 186 μg BIDOPN-375 372 μg BID
Change in Olfactory Impairment From Baseline to Week 24/ET as Measured by the Smell Identification Test (SIT)™0.23 ± 0.9542.63 ± 0.9590.70 ± 0.972
SecondaryChange in Baseline to Week 24/ET as Measured by the Euroqol 5-dimension (EQ-5D) Instrument

The EQ-5D consists of the EQ-5D descriptive system and the EQ visual analogue scale (EQ VAS). The outcome measured for this study was the EQ VAS, which records the subject's self-rated health on a vertical visual analogue scale, where the endpoints are labelled "The best health you can imagine" and "The worst health you can imagine". The VAS can be used as a quantitative measure of health outcome that reflects the subject's own judgement. VAS scores range from 0 (worst health you can imagine) to 100 (best health you can imagine).

Time frame:
24 Weeks
Reported as:
Least squares mean · score on a scale
Change in Baseline to Week 24/ET as Measured by the Euroqol 5-dimension (EQ-5D) Instrument
score on a scalePlaceboOPN-375 186 μg BIDOPN-375 372 μg BID
Change in Baseline to Week 24/ET as Measured by the Euroqol 5-dimension (EQ-5D) Instrument2.10 ± 1.8899.67 ± 1.8807.30 ± 1.891
SecondaryChange in Baseline to Week 24/ET as Measured by the Short-Form 6-Dimension (SF-6D) Instrument

The SF-6D is a single health state index derived from the 11 items from the SF-36v2. SF-6D scores range from 0 (worst health state) to 1 (best health state). The values provided in the outcome data are calculated by subtracting the score reported at baseline from the score reported at Visit 6 (Week 24).

Time frame:
24 Weeks
Reported as:
Least squares mean · score on a scale
Change in Baseline to Week 24/ET as Measured by the Short-Form 6-Dimension (SF-6D) Instrument
score on a scalePlaceboOPN-375 186 μg BIDOPN-375 372 μg BID
Change in Baseline to Week 24/ET as Measured by the Short-Form 6-Dimension (SF-6D) Instrument0.00 ± 0.0160.06 ± 0.0160.05 ± 0.016
SecondaryPercentage of Subjects Indicating That They Are Willing to Consider Sinus Surgery at Baseline and Week 24

Percentage of subjects indicating that they are willing to consider Sinus Surgery. This is a comparison of health economic measures and data was obtained by direct questioning of the subjects during study visits.

Time frame:
Baseline, Week 24
Reported as:
Count of participants · Participants
Percentage of Subjects Indicating That They Are Willing to Consider Sinus Surgery at Baseline and Week 24
ParticipantsPlaceboOPN-375 186 μg BIDOPN-375 372 μg BID
Baseline384038
Week 24353633
SecondaryPercentage of Subjects Who Meet the Minimal Objective Criteria for Surgical Intervention at Baseline and Week 24.

Percentage of subjects who meet the minimal objective criteria for surgical intervention based on completion of a surgical intervention assessment questionnaire for the investigator.

Time frame:
Baseline, Week 24
Reported as:
Count of participants · Participants
Percentage of Subjects Who Meet the Minimal Objective Criteria for Surgical Intervention at Baseline and Week 24.
ParticipantsPlaceboOPN-375 186 μg BIDOPN-375 372 μg BID
Baseline15615
Week 2414310
SecondaryPercentage of Subjects Approved for Surgery Who no Longer Elect to Undergo a Surgery

Outcome value presented here is the percent of subjects who are approved for surgery but no longer elect to undergo a surgery. Number of participants analyzed indicates the total number of participants for whom this analysis was completed.

Time frame:
Week 24
Reported as:
Count of participants · Participants
Percentage of Subjects Approved for Surgery Who no Longer Elect to Undergo a Surgery
ParticipantsPlaceboOPN-375 186 μg BIDOPN-375 372 μg BID
Percentage of Subjects Approved for Surgery Who no Longer Elect to Undergo a Surgery353336
Other pre-specifiedEvaluation of Safety by Recording the Severity of Adverse Events (AEs)

Assessment of safety by measuring severity of AEs using scale with 1=mild, 2=moderate, 3=severe

Time frame:
24 Weeks
Reported as:
Count of participants · Participants
Evaluation of Safety by Recording the Severity of Adverse Events (AEs)
ParticipantsPlaceboOPN-375 186 μg BIDOPN-375 372 μg BID
Mild131522
Moderate17819
Severe112
Other pre-specifiedEvaluation of Safety-Nasal Examination

Assessed in nasal examination worksheet which includes recording the presence of any epistaxis, septal erosion/perforation, ulceration/erosion of area other than septum.

Time frame:
24 Weeks
Reported as:
Count of participants · Participants
Evaluation of Safety-Nasal Examination
ParticipantsPlaceboOPN-375 186 μg BIDOPN-375 372 μg BID
Epistaxis — None717068
Epistaxis — Present014
Septal erosion/perforation — None707170
Septal erosion/perforation — Present102
Ulceration/Erosion — None717172
Ulceration/Erosion — Present000
Mucosal candidiasis — None717172
Mucosal candidiasis — Present000
Other pre-specifiedEvaluation of Safety Measuring Vital Signs- Blood Pressure

Includes systolic and diastolic blood pressure measurements in millimeter of mercury (mmHg)

Time frame:
24 Weeks
Reported as:
Mean · mmHg
Evaluation of Safety Measuring Vital Signs- Blood Pressure
mmHgPlaceboOPN-375 186 μg BIDOPN-375 372 μg BID
Systolic Blood Pressure126.2 ± 11.30124.0 ± 13.26126.9 ± 11.94
Diastolic Blood Pressure78.1 ± 8.2976.5 ± 7.8878.5 ± 7.69
Other pre-specifiedEvaluation of Safety Measuring Vital Signs- Pulse

Measure pulse in beats per minute (bpm)

Time frame:
24 Weeks
Reported as:
Mean · beats per minute
Evaluation of Safety Measuring Vital Signs- Pulse
beats per minutePlaceboOPN-375 186 μg BIDOPN-375 372 μg BID
Evaluation of Safety Measuring Vital Signs- Pulse73.7 ± 7.3774.1 ± 6.7672.1 ± 8.18
Other pre-specifiedEvaluation of Safety Measuring Vital Signs- Weight

Assessment of safety from physical examination-weight measured in kg or lb

Time frame:
24 Weeks
Reported as:
Mean · kg
Evaluation of Safety Measuring Vital Signs- Weight
kgPlaceboOPN-375 186 μg BIDOPN-375 372 μg BID
Evaluation of Safety Measuring Vital Signs- Weight77.86 ± 16.52776.30 ± 15.25081.14 ± 20.091
Other pre-specifiedEvaluation of Safety - Monitoring Concomitant Medication Usage

Assessment for safety from the collection of information for concomitant medications usage. Top 5 reported con-meds by therapeutic class are listed for this outcome.

Time frame:
24 Weeks
Reported as:
Count of participants · Participants
Evaluation of Safety - Monitoring Concomitant Medication Usage
ParticipantsPlaceboOPN-375 186 μg BIDOPN-375 372 μg BID
Other Nasal Preparations (includes sodium chloride and sea water)221515
Adrenergics in combination with corticosteroids or other drugs15919
Glucocorticoids1197
Selective Beta-2-adrenoreceptor Agonists1148
HMG-CoA Reductase Inhibitors879

Adverse events

Collected over Pretreatment (Screening/Run-in) period to end of treatment (Week 24). Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/75 (0%)0/75 (0%)31/75 (41.3%)
OPN-375 186 μg BID0/73 (0%)1/73 (1.4%)17/73 (23.3%)
OPN-375 372 μg BID0/74 (0%)4/74 (5.4%)43/74 (58.1%)
Most frequent serious events
Most frequent serious events
EventPlaceboOPN-375 186 μg BIDOPN-375 372 μg BID
Invasive ductal breast carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/751/730/74
Rectal adenocarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/750/731/74
AsthmaRespiratory, thoracic and mediastinal disorders0/750/731/74
Atrial fibrillationCardiac disorders0/750/731/74
COVID-19 PneumoniaInfections and infestations0/750/731/74
Most frequent other events
Showing 10 of 22
Most frequent other events
EventPlaceboOPN-375 186 μg BIDOPN-375 372 μg BID
COVID-19Infections and infestations2/753/737/74
HeadacheNervous system disorders6/752/737/74
EpistaxisRespiratory, thoracic and mediastinal disorders0/754/737/74
NasopharyngitisInfections and infestations5/753/734/74
Chronic SinusitisInfections and infestations5/751/733/74
AsthmaRespiratory, thoracic and mediastinal disorders4/750/732/74
Nasal polypsRespiratory, thoracic and mediastinal disorders4/750/730/74
DepressionPsychiatric disorders1/750/733/74
SinusitisInfections and infestations3/750/732/74
Upper respiratory tract infectionInfections and infestations2/752/731/74

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)PlaceboOPN-375 186 μg BIDOPN-375 372 μg BIDTotal
<=18 years0000
Between 18 and 65 years676563195
>=65 years881127
Age, Continuous
Age, Continuous(years)PlaceboOPN-375 186 μg BIDOPN-375 372 μg BIDTotal
Mean48.7 ± 12.3447.1 ± 13.7549.4 ± 13.5348.4 ± 13.19
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboOPN-375 186 μg BIDOPN-375 372 μg BIDTotal
Female324039111
Male433335111
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboOPN-375 186 μg BIDOPN-375 372 μg BIDTotal
Hispanic or Latino1203
Not Hispanic or Latino747174219
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboOPN-375 186 μg BIDOPN-375 372 μg BIDTotal
American Indian or Alaska Native0000
Asian0000
Native Hawaiian or Other Pacific Islander0000
Black or African American1102
White747273219
More than one race0000
Unknown or Not Reported0011
Region of Enrollment
Region of Enrollment(Participants)PlaceboOPN-375 186 μg BIDOPN-375 372 μg BIDTotal
New Zealand1001
Romania69924
United States551222
Czechia94518
Poland363730103
United Kingdom0011
Georgia78722
Australia2125
Bulgaria66416
Spain33410
Intranasal corticosteroid treatment for chronic sinusitis within last 10 years
Intranasal corticosteroid treatment for chronic sinusitis within last 10 years(participants)PlaceboOPN-375 186 μg BIDOPN-375 372 μg BIDTotal
Mometasone furoate382835101
Fluticasone proprionate20151651
Fluticasone furoate28232475
Budesonide73212
Beclomethasone2226
Triamcinolone2215
Fluticasone and azelastine14131340
Other2226
Prior Sinusitis Surgery
Prior Sinusitis Surgery(participants)PlaceboOPN-375 186 μg BIDOPN-375 372 μg BIDTotal
Any Surgery32303193
Endoscopic sinus surgery26283084
Balloon sinuplasty0011
Polypectomy alone52714
Other surgery73717

3 further baseline measures are reported on the registry.

08

Study locations

87 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35233, United States
  • Sacramento Ear, Nose & Throat Surgical and Medical Group Inc
    Folsom, California 95630, United States
  • BioSolutions Clinical Research Center
    La Mesa, California 91942-3007, United States
  • Veterans Administration Greater Los Angeles Healthcare System
    Los Angeles, California 90073, United States
  • Sacramento Ear, Nose & Throat Surgical and Medical Group
    Roseville, California 95661, United States
  • Asthma and Allergy Associates
    Colorado Springs, Colorado 80907, United States
  • Sher Allergy Specialists
    Largo, Florida 33778, United States
  • University of Miami Miller School of Medicine
    Miami, Florida 33136, United States
  • Treasure Valley Medical Research
    Boise, Idaho 83706, United States
  • Best Clinical Trials
    New Orleans, Louisiana 70115, United States
  • University of Missouri, Dept of Otorlaryngology
    Columbia, Missouri 65212, United States
  • Mount Sinai Downtown Union Square
    New York, New York 10003, United States
  • Northwell Health at ENT and Allergy Associates
    New York, New York 10016, United States
  • Charlotte Eye Ear Nose and Throat Assoc., PA
    Matthews, North Carolina 28105, United States
  • University of Pittsburgh Medical Center
    Pittsburgh, Pennsylvania 15219, United States
  • ENT & Allergy Partners, LLC
    Summerville, South Carolina 29486, United States
  • Pasha Snoring & Sinus Center
    Houston, Texas 77082, United States
  • University of Utah
    Salt Lake City, Utah 84132, United States
  • Eastern Virginia Medical School
    Norfolk, Virginia 23507, United States
  • Allergy, Asthma & Sinus Center, SC
    Greenfield, Wisconsin 53228, United States
  • Otopure Pty Ltd
    Bella Vista, New South Wales 2153, Australia
  • Vale Medical Practice
    Brookvale, New South Wales 2100, Australia
  • Australian Clinical Research Network
    Maroubra, New South Wales 2035, Australia
  • Browns Plains Family Practice
    Browns Plains, Queensland 4118, Australia
  • Casey Superclinic
    Berwick, Victoria 3806, Australia
  • Camberwell Road Medical Practice
    Hawthorn East, Victoria 3123, Australia
  • Mirrabooka Medical Centre
    Mirrabooka, Western Australia 6061, Australia
  • Latitude Clinical Research
    Spearwood, Western Australia 6163, Australia
  • UMHAT Kaspela EOOD
    Plovdiv, 4002, Bulgaria
  • Medical Center Iskar EOOD
    Sofia, 1000, Bulgaria
  • MHAT Serdika EOOD
    Sofia, 1303, Bulgaria
  • MC N.I. Pirogov EOOD
    Sofia, 1606, Bulgaria
  • MHAT - Central Clinical Base Sofia Medical Institute Ministry of Interior
    Sofia, 1606, Bulgaria
  • MMA MHAT - Sofia
    Sofia, 1606, Bulgaria
  • DCC Convex EOOD
    Sofia, 1680, Bulgaria
  • MHAT Trakiya EOOD
    Stara Zagora, 6000, Bulgaria
  • DCC "Mladost - M Varna" OOD
    Varna, 9020, Bulgaria
  • Nemocnice Rudolfa a Stefanie Benesov, a.s., ORL oddeleni
    Benesov, 256 01, Czechia
  • FN Hradec Kralove, Klinika ORL
    Hradec Králové, 500 05, Czechia
  • Pro-audio s.r.o.
    Mladá Boleslav, 293 01, Czechia
  • MUDr. Pavel Navratil, ORL ambulance
    Olomouc, 779 00, Czechia
  • Nemocnice Pardubického kraje - Pardubická nemocnice
    Pardubice, 532 03, Czechia
  • AXON Clinical s.r.o.
    Prague, 150 00, Czechia
  • VFN v Praze, oddeleni ORL
    Praha, 128 08, Czechia
  • Ltd Acad. Fridon Todua Medical Center- Research
    Tbilisi, 0112, Georgia
  • Ltd Israel-Georgian Medical Research Clinic - Helsicore
    Tbilisi, 0112, Georgia
  • JSC Curatio
    Tbilisi, 0114, Georgia
  • Ltd New Hospitals
    Tbilisi, 0114, Georgia
  • Ltd Simon Khechinashvili University Hospital
    Tbilisi, 0179, Georgia
  • Ltd Tbilisi Heart Center
    Tbilisi, 0186, Georgia
  • Ltd Aversi Clinic
    Tbilisi, 1060, Georgia
  • P3 Research Tauranga Ltd.
    Tauranga, Bay Of Plenty 3110, New Zealand
  • Optimal Clinical Trials
    Auckland, 1010, New Zealand
  • Clinical Trials New Zealand
    Hamilton, 3206, New Zealand
  • P3 Research Wellington Ltd.
    Wellington, 6021, New Zealand
  • Przychodnia "Narutowicza"
    Inowrocław, Kujawsko-Pomorskie 88-100, Poland
  • Centrum Medyczne All-Med
    Kraków, Malopolskie 30-033, Poland
  • Indywidualna Specjalistyczna Praktyka Lekarska J. Slifirski
    Kęty, Malopolskie 32-650, Poland
  • ReumaClinic Gabinet Reumatologiczny
    Białystok, 15-166, Poland
  • Centrum Medyczne MedSen Sp. z o.o.
    Białystok, 15-691, Poland
  • Centrum Medyczne Kwiatowa
    Bydgoszcz, 85-047, Poland
  • Synexus Polska Sp. Z o. o., Oddzial w Gdyni ul. Luzycka 3c
    Gdynia, 81-537, Poland
  • Centrum Medyczne Angelius Provita
    Katowice, 40-611, Poland
  • Mini-Clinic Paweł Białogłowski
    Lancut, 37-100, Poland
  • Centrum Alergologii Specjalistyczna Przychodnia Alergologiczna
    Lublin, 20-552, Poland
  • Centrum Medyczne Lucyna Andrzej Dymek S.C.
    Strzelce Opolskie, 47-100, Poland
  • NZOZ "Ignis" dr med. Alicja Lobinska
    Swidnik, 21-040, Poland
  • NZOZ Centrum Medyczne LiMED
    Tarnowskie Góry, 42-600, Poland
  • Synexus Polska Sp. z.o.o. Oddzial w Warszawie
    Warszawa, 01-192, Poland
  • Synexus Polska Sp.zo.o. Oddział we Wrocławiu
    Wroclaw, 50-381, Poland
  • NZOZ Przychodnia Medycyny Rodzinnej
    Świętochłowice, 41-600, Poland
  • S.C. Centrul Medical Unirea S.R.L. Brasov
    Braşov, 500091, Romania
  • SC Centrul Medical Unirea srl, Policlinica Primaverii
    Bucharest, 011858, Romania
  • S.C. Euroclinic Hospital S.A.
    Bucharest, 014461, Romania
  • Centrul Medical Cardiomed Cluj, Cabinet ORL
    Cluj-Napoca, 400015, Romania
  • Spitalul Clinic Universitar CF Cluj-Napoca
    Cluj-Napoca, 400015, Romania
  • S.C. Centrul Medical Unirea S.R.L - IASI, Campus Medical Iasi - Cabinet ORL
    Iaşi, 700023, Romania
  • Hospital Universitario de Jerez de la Frontera
    Jerez De La Frontera, Cadiz 11407, Spain
  • Hospital Universitario de Fuenlabrada Servicio de Otorrinolaringología
    Fuenlabrada, Madrid 28942, Spain
  • Hospital Universitario de Torrejon
    Torrejon de Ardoz, Madrid 28850, Spain
  • Centro Médico Teknon
    Barcelona, 08022, Spain
  • Hospital Universitari Clinic de Barcelona
    Barcelona, 08036, Spain
  • Hospital Universitari de Bellvitge, Servicio de Otorrinolaringología
    L'Hospitalet De Llobregat, 08907, Spain
  • Consulta 164 Servicio ORL Hospital Clinico Universitario de Santiago de Compostela
    Santiago De Compostela, 15706, Spain
  • Hospital Universitario Virgen Macarena
    Seville, 41009, Spain
  • Hospital Universitario i Politecnic la Fe
    Valencia, 46026, Spain
  • King's Mill Hospital
    Sutton-in-Ashfield, Nottinghamshire NG17 4JL, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2019 to primary completion in May 2022, 34 months.

Results were first posted in Dec 2023, 1 year 7 months after primary completion.

Of 24 phase 3 interventional studies under Rhinosinusitis, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 37. This study's 34 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
May 20, 2019
First posted
May 23, 2019
StartActual
Jun 6, 2019
Primary completionActual
May 4, 2022
CompletionActual
May 4, 2022
Results first posted
Dec 21, 2023
Last update
Dec 21, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 21, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03960580
Lead sponsor
Optinose US Inc.
Responsible party
Sponsor
First posted
May 23, 2019
Start date
Jun 6, 2019
Primary completion
May 4, 2022
Completion
May 4, 2022
Results posted
Dec 21, 2023
Last update
Dec 21, 2023

Study contacts

Jennifer Carothers
study director · Optinose US Inc.
John Messina
study chair · Optinose US Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fluticasone

Start the discussion